The size of the biomarkers market in the European market is expected to reach USD 19.07 billion by 2025 from USD 10.39 billion in 2020, growing at a CAGR of 12.90% during the forecast period.
Biomarkers are described as the biological molecules or genes that assist in crucial clinical decisions and diagnosis of health conditions in patients. These are also known as molecular markers or signature molecules and used to analyze the pharmacologic responses, biological & pathological conditions. Biomarkers are found extensively in body fluids and tissues. Biomarkers are helpful in drug discovery & development processes and assessment of disease conditions.
Increasing healthcare expenditure, growing the aging population, rising number of cancer patients, increasing demand for diagnostics, raising awareness on healthy lifestyles are driving the growth of the biomarkers market in Europe. Besides, the rising utilization of biomarkers in clinical trials & drug discovery and growing technologies in biomarkers discovery is further stimulating the growth of the biomarkers market in Europe.
However, the requirement of qualitative biomarkers validation and the high cost of the development of the biomarkers are expected to restrain the growth of the biomarkers market in Europe.
This research report segmented and sub-segmented into the following categories:
Top companies in this market
Companies dominating the European Biomarkers Market profiled in this report are Bio-Rad Laboratories (U.S.), Qiagen N.V. (Netherlands), Enzo Biochem (U.S.), PerkinElmer, Inc. (U.S.), Merck & Co, Inc. (U.S.), EKF Diagnostics Holdings plc. (U.S.), Meso Scale Diagnostics, LLC (U.S.), Singulex, Inc. (U.S.), BioSims Technologies (France), Cisbio Bioassays (France) and Signosis, Inc. (U.S.)
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Product
5.1.1 Introduction
5.1.2 Consumables
5.1.3 Software
5.1.4 Services Growth Hormone Therapy
5.2 Type
5.2.1 Introduction
5.2.2 Safety Biomarkers
5.2.3 Efficacy Biomarkers
5.2.4 Validation Biomarkers
5.3 Application
5.3.1 Introduction
5.3.2 Diagnostics Development
5.3.3 Drug Discovery and Development
5.3.4 Personalised Medicine
5.3.5 Disease Risk Assessment
5.3.6 Other Applications
5.4 Disease Indications
5.4.1 Introduction
5.4.2 Cancer
5.4.3 CardiovascularDisorders
5.4.4 Neurological Disorders
5.4.5 Immunological Disorders
5.4.6 Other Diseases
6.1 Introduction
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Bio-Rad Laboratories (U.S.)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Qiagen N.V. (Netherlands)
8.3 Enzo Biochem (U.S.)
8.4 PerkinElmer, Inc. (U.S.)
8.5 Merck & Co, Inc. (U.S.)
8.6 EKF Diagnostics Holdings plc. (U.S.)
8.7 Meso Scale Diagnostics, LLC (U.S.)
8.8 Singulex, Inc. (U.S.)
8.9 BioSims Technologies (France)
8.10 Cisbio Bioassays (France)
8.11 Signosis, Inc. (U.S.)
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
Feb 2020
